COSCIENS Biopharma Inc. (CSCIF)
OTCMKTS · Delayed Price · Currency is USD
2.500
+0.100 (4.17%)
At close: Sep 8, 2025
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $2.75M in the quarter ending June 30, 2025, with 17.63% growth. This brings the company's revenue in the last twelve months to $9.44M, up 24.89% year-over-year. In the year 2024, COSCIENS Biopharma had annual revenue of $9.59M with 34.22% growth.
Revenue (ttm)
9.44M
Revenue Growth
+24.89%
P/S Ratio
0.85
Revenue / Employee
236.05K
Employees
40
Market Cap
8.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.59M | 2.44M | 34.22% |
| Dec 31, 2023 | 7.14M | -7.43M | -50.98% |
| Dec 31, 2022 | 14.57M | 9.31M | 177.03% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Federal National Mortgage Association | 28.89B |
| Federal Home Loan Mortgage | 22.97B |
| Alpine Auto Brokers | 129.78K |
| Central Bancompany | 851.25M |
| First National of Nebraska | 1.89B |
| Procaps Group | 423.75M |
| Jingbo Technology | 2.29M |
| Wilson Bank Holding Company | 197.85M |
COSCIENS Biopharma News
- 25 days ago - COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 6 months ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire